IPN60300 / Ipsen, Foreseen Biotech - LARVOL DELTA

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=102 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=102 | Not yet recruiting | Sponsor: Ipsen

First-in-human • New P1/2 trial • Oncology • Solid Tumor

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential (GlobeNewswire) - "Ipsen...and Foreseen Biotechnology...announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation and metastasis....The agreement gives Ipsen exclusive worldwide rights to develop, manufacture and commercialize FS001....Foreseen Biotechnology is eligible to receive up to $1.03bn comprising upfront, development, regulatory and commercial milestone payments, and tiered royalties on global sales, contingent upon successful development and regulatory approvals. Under the terms of the agreement, Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical-development, manufacturing, and global commercialization activities."

Licensing / partnership • Solid Tumor